Anti-Inflammatory and Cardioprotective Effects of Tadalafil in Diabetic Mice

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Varma, Amit ^a   Das, Anindita ^a   Hoke, Nicholas N ^a   Durrant, David E ^a   Salloum, Fadi N ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TADALAFIL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL DEATH; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INFLAMMATION; ISOLATED HEART; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OBESITY; PROTEIN ANALYSIS; REOXYGENATION; REPERFUSION INJURY;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION SCHEDULE; FASTING; INTERLEUKIN-1BETA; MALE; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NECROSIS; OBESITY; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, LEPTIN; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS;

EID: 84866679788     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045243     Document Type: Article

References (70)

1. The American Diabetes Association- diabetes statistics website. Available: http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed: 2012 August 3.
2. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, et al. (2007) Chronic treatment with sildenafil improves energy balance and insulin action in high-fat-fed conscious mice. Diabetes 57: 1025-1033.
3. Deyoung L, Chung E, Kovac JR, Romano W, Brock GB, (2012) Daily use of sildenafil improves endothelial function in men with type 2 diabetes. J Androl 33: 176-180.
4. Wen Y, Skidmore JC, Porter-Turner MM, Rea CA, Khokher MA, et al. (2002) Relationship of glycation, antioxidant status and oxidative stress to vascular damage in diabetes. Diabetes Obes Metab 4: 305-308.
5. Soloman H, Man JW, Jackson G, (2003) Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89: 251-254.
6. Versari A (2009) Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care (Suppl 2): S314-S321.
7. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, et al. (2001) Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104: 342-345.
8. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD, (2000) Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49: 684-687.
9. Roy D, Perreault M, Marette A, (1998) Insulin stimulation of glucose uptake in skeletal muscles and adipose tissue in vivo is NO dependent. Am J Physiol 274: E692-E699.
10. Baron AD, Zhu JS, Marshall S, Irsula O, Brechtel G, et al. (1995) Insulin resistance after hypertension induced by the nitric oxide synthase inhibitor L-NMMA in rats. Am J Physiol 269: E709-E715.
11. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, et al. (2003) Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly 133: 360-363.
12. Luo L, Dai D, Cheng YS, Zhang Q, Yuan WH, et al. (2011) Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS, NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats. J Pharm and Pharmacol 63: 943-951.
13. Frey MK, Lang I, (2012) Tadalafil for the treatment of pulmonary hypertension. Expert Opin Pharmacother 13: 747-755.
14. Ockaili RA, Salloum FN, Kukreja RC, (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitrochondrial KATP channels in rabbits. Am J Physiol Heart Circ Physiol 283: H1263-H1269.
15. Salloum FN, Ockaili RA, Wittkamp M, Marwaha VR, Kukreja RC, (2006) Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial KATP channels in rabbits. J Mol Cell Cardiol 40: 405-411.
16. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, et al. (2007) Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitrochondrial KATP channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 42: 453-458.
17. Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC, (2009) ERK phosphorylation mediates sildenafil induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 296: H1236-H1243.
18. Salloum FN, Chau VQ, Hoke NN, Abbate A, Varma A, et al. (2009) Phosphodiesterase-5 inhibitor tadalafil protects against myocardial ischemia/reperfusion through protein kinase-g dependent generation of hydrogen sulfide. Circulation 120: S31-S36.
19. Chau VQ, Salloum FN, Hoke NN, Abbate A, Kukreja RC, (2011) Mitigation of the progression of the progression of heart failure with sildenafil involves the inhibition of RhoA/Rho-Kinase pathway. Am J Physiol Heart Circ Physiol 300: H2272-H2279.
20. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, et al. (2008) Sildenafil (viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294: H1398-H1406.
21. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, et al. (2010) Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A 107: 18202-18207.
22. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC, (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111: 1601-1610.
23. Koka S, Das A, Zhu SG, Durrant D, Xi L, et al. (2010) Long acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 334: 1023-1030.
24. Salloum FN, Yin C, Kukreja RC, (2003) Sildenafil induces delayed pre-conditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92: 595-597.
25. Das A, Xi L, Kukreja RC, (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of NO signaling. J Biol Chem 280: 12944-12955.
26. Das A, Xi L, Kukreja RC, (2008) Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3-beta. J Biol Chem 283: 29572-29585.
27. Salloum FN, Das A, Samidurai A, Hoke NN, Chau VQ, et al. (2012) Cinaciguat, a novel activator of soluable guanylate cyclase protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol 302: H1347-H1354.
28. Schafer A, Fraccarollo D, Pfortsch S, Flierl U, Vogt C, et al. (2008) Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol 153: 886-893.
29. Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, et al. (2005) Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 28: 260-266.
30. Montosri F, Briganti A, Salonia A, Rigatti P, Burnett AL, (2006) Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur Urol 49: 979-986.
31. Lerman A, Zeiher AM, (2005) Endothelial function: cardiac events. Circulation 111: 363-368.
32. Gazzaruso C, Sebastiano SV, Pujia A, Coppola A, Vezzoli M, et al. (2008) Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease. J Am Coll Cardiol 51: 2040-2044.
33. Cui R, Iso H, Pi J, Kumagai Y, Yamagishi K, et al. (2007) Metabolic syndrome and urinary cGMP excretion in the general population. Atheroscler 190: 423-428.
34. Franks PW, Luan J, Barroso I, Brage S, Gonzalez Sanchez JL, et al. (2005) Variation in the eNOS gene modifies the association between total energy expenditure and glucose intolerance. Diabetes 54: 2795-2801.
35. Aversa A, Greco E, Buzziches R, Pili M, Rosano G, et al. (2007) Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 19: 200-207.
36. DeSouza C, Parulkar A, Lumpkin D, Akers D, Fonesca VA, (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25: 1336-1339.
37. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, et al. (2008) Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 25: 37-44.
38. Van der Mieren G, Nevelsteen I, Vanderper A, Oosterlinck W, Flameng W, et al. (2012) Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury. Cardiovasc Diabetol 11: 89 [Epub ahead of print].
39. Miki T, Itoh T, Sunaga D, Miura T (2012) Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 11: 67-[Epub ahead of print].
40. Bugger H, Abel ED, (2008) Molecular mechanisms for myocardial dysfunction in the metabolic syndrome. ClinSci 114: 195-210.
41. Abozguia K, Clarke K, Lee L, Frenneaux M, (2006) Modification of myocardial substrate use as therapy for heart failure. Nat Clin Pract Cardiovasc Med 3: 490-498.
42. Hwang YC, Sato C, Tsai JY, Yan S, Bakr S, et al. (2002) Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J 16: 243-245.
43. Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, et al. (2005) Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci 1043: 702-709.
44. Rui T, Zhang J, Xu X, Yao Y, Kao R, et al. (2012) Reduction of IL-33 expression exaggerates ischemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc Res 94: 370-378.
45. Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, et al. (2003) The discover of tadalafil: a novel and highly selective PDE5 inhibitor: 1:5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. J Med Chem 46: 4525-4532.
46. Hummell KP, Dickie MM, Coleman DL, (1966) Diabetes, a new mutation in the mouse. Science 153: 1127-1128.
47. Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, et al. (1996) Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271: 994-996.
48. Carroll R, Carley AN, Dyck JR, Severson DL, (2005) Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts. Am J Physiol Endocrinol Metab 288: E900-E906.
49. The Jackson Laboratory wesbite. Available: http://jaxmice.jax.org/strain/000642.html. Accessed: 2012 July 31.
50. Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA, et al. (1999) Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84: 43-52.
51. Zhou YY, Wang SQ, Zhu W, Chruscinski A, Kobilka B, et al. (2000) Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. Am J Physiol Heart Circ Physiol 279: H429-H436.
52. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, et al. (2009) Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Med 15: 930-939.
53. Ghanim H, Korzeniewski K, Sia CL, Abuaysheh S, Lohano T, et al. (2010) Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care 33: 1103-1108.
54. Capurso C, Capurso A (2012) From excess adiposity to insulin resistance: The role of free fatty acids. Vascul Pharmacol 2012 May 15.
55. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM, (2001) C-Reactive Protein, Interleukin-6 and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334.
56. Fisman EZ, Tenenbaum A, (2010) The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc Diabetol 9: 62.
57. Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, et al. (2010) Interleukin-6 deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetelogia 2010; 53: 2431-2441]. Diabetelogia 53: 2431-2441.
58. Koka S, Xi L, Kukreja RC, (2012) Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type II diabetic hearts. Basic Res Cardiol 107: 249.
59. McGaffin KR, Sun CK, Rager JJ, Romano LC, Zou B, et al. (2008) Leptin signalling reduces the severity of cardiac dysfunction and remodeling after chronic ischaemic injury. Cardiovasc Res 77: 54-63.
60. McGaffin KR, Zou B, McTiernan CF, O'Donnell CP, (2009) Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res 83: 313-324.
61. Gillies HC, Roblin D, Jackson G, (2002) Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 86: 131-141.
62. Sabatinin S, Sgro P, Duranti G, Ceci R, Di Luigi L, (2011) Tadalafil alters energy metabolism in C2C12 skeletal muscle cells. Acta Biochim Pol 58: 237-241.
63. Haas B, Mayer P, Jennissen K, Scholz D, Diaz Berriel M, et al. (2009) Protein kinase G controls bown fat cell differentiation and mitochondrial biogenesis. Sci Signal 2: ra78.
64. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, et al. (2003) Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide synthase. Science 299: 896-899.
65. Nisoli E, Clementi E, Tonello C, Sciorati C, Briscini L, et al. (1998) Effects of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary cultures. Br J Pharmacol 125: 888-894.
66. Gao L, Mann GE, (2009) Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signaling. Cardiovasc Res 82: 9-20.
67. Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, et al. (2007) Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 583: 9-24.
68. Brownlee M, (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.
69. Cosentino F, Hishikawa K, Katusic ZS, Luschner TF, (1997) High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96: 25-28.
70. Ding H, Aljofan M, Triggle CR, (2007) Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J Cell Physiol 212: 682-689.